Atopic Dermatitis in Visible Areas Is a Real Challenge!

0 SAR
Checkout

Overview

in this video, Dr. Naiem T. Issa reviews Week 16 data from the ADvocate 1, ADvocate 2,
and ADhere studies, highlighting the efficacy of Ebglyss® (lebrikizumab) 250 mg Q2W
in improving atopic dermatitis in visible areas such as the hands and face, with or without
topical corticosteroids. He also presents a real-world case of a 40-year-old patient with
longstanding eczema, demonstrating marked improvements in BSA and itch severity
within 8 weeks of treatment with lebrikizumab.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • ● Review Week 16 efficacy of lebrikizumab 250 mg Q2W in improving
    atopic dermatitis on the hands and face.
    ● Highlight efficacy with and without topical corticosteroids.
    ● Demonstrate real-world effectiveness through a dupilumab-
    refractory patient case with improvements in BSA and Itch NRS.
    ● Reinforce the key message: rapid, visible skin clearance with
    lebrikizumab.

     

     

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    PP-LK-SA-0265


Related Classes